Addition of Nucleic Acid Polymers Improves Outcomes of Patients With HBV Infection

Addition of nucleic acid polymers (NAPs), which inhibit assembly and secretion of hepatitis B virus (HBV) subviral particles, to tenofovir disoproxil fumarate (TDF) and pegIFN therapy significantly increased rates of HBsAg loss and seroconversion, and functional cure, after therapy, researchers report in Gastroenterology. Chronic HBV infection causes progressive liver fibrosis,

Read more
  • Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

Efficacy and Safety of Besifovir Dipivoxil Maleate in a Phase 3 Trial of Patients With Chronic HBV Infection

The efficacy of 48 weeks treatment with besifovir dipivoxil maleate (BSV) for chronic hepatitis B virus (HBV) infection is comparable to that of tenofovir disoproxil fumarate (TDF), with durable effects for 96 weeks, researchers report in the August issue of Clinical Gastroenterology and Hepatology. BSV has a better safety profile

Read more